Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12
Similar Tracks
INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer
OncBrothers: Practice-Changing Cancer Discussions
2nd line treatment in advanced HCC and when to switch
OncBrothers: Practice-Changing Cancer Discussions
Breast Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Erika Hamilton
OncBrothers: Practice-Changing Cancer Discussions
GU Cancer ESMO 2024 Highlights: Key Studies Discussed NIAGARA, TiNiVO-2, PEACE-3, CONTACT-02
OncBrothers: Practice-Changing Cancer Discussions
Key Discussions on CML: Pakistan - December2024 - Managing CML post-BMT relapse
International CML Foundation
GU Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Toni Choueiri
OncBrothers: Practice-Changing Cancer Discussions
How to Approach to Ovarian Cancer from Community Oncology Perspective
OncBrothers: Practice-Changing Cancer Discussions
Regional Discussion Group Africa 20th Nov 24 Part 2 of 2: 2023 ELN laboratory recommendations
International CML Foundation
GI Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Mark Lewis
OncBrothers: Practice-Changing Cancer Discussions
WCLC 2024 Highlights - Exploring Latest Advances in Lung Cancer Treatment
OncBrothers: Practice-Changing Cancer Discussions
How to Approach to Endometrial Cancer from Community Oncology Perspective
OncBrothers: Practice-Changing Cancer Discussions